| 588.38 7.87 (1.36%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 710.01 | 1-year : | 829.29 |
| Resists | First : | 607.89 | Second : | 710.01 |
| Pivot price | 573.02  |
|||
| Supports | First : | 552.08 | Second : | 517.59 |
| MAs | MA(5) : | 580.52 |
MA(20) : | 562.34 |
| MA(100) : | 505.82 |
MA(250) : | 413.38 |
|
| MACD | MACD : | 16.5 |
Signal : | 16.6  |
| %K %D | K(14,3) : | 70.4 |
D(3) : | 67.9 |
| RSI | RSI(14): 64.3 |
|||
| 52-week | High : | 607.89 | Low : | 272.11 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ UTHR ] has closed below upper band by 26.2%. Bollinger Bands are 25.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 593.21 - 595.41 | 595.41 - 597.18 |
| Low: | 568.69 - 571.44 | 571.44 - 573.65 |
| Close: | 584.2 - 588.5 | 588.5 - 591.95 |
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Sun, 19 Apr 2026
UTHR PE Ratio & Valuation, Is UTHR Overvalued - Intellectia AI
Sun, 19 Apr 2026
The Bull Case For United Therapeutics (UTHR) Could Change Following FDA RMAT Status For miroliverELAP - Yahoo Finance
Sat, 18 Apr 2026
United Therapeutics Corporation (UTHR) Completes Phase 3 Enrollment for Promising PAH Drug Ralinepag - MSN
Fri, 17 Apr 2026
United Therapeutics CFO Edgemond sells $5.7M in UTHR stock - Investing.com
Fri, 17 Apr 2026
3 Reasons Investors Love United Therapeutics (UTHR) - Yahoo Finance
Fri, 17 Apr 2026
Lbp Am Sa Takes Position in United Therapeutics Corporation $UTHR - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 44 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 1.9 (%) |
| Held by Institutions | 98 (%) |
| Shares Short | 2,840 (K) |
| Shares Short P.Month | 1,840 (K) |
| EPS | 27.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 162.6 |
| Profit Margin | 41.9 % |
| Operating Margin | 44.9 % |
| Return on Assets (ttm) | 12.4 % |
| Return on Equity (ttm) | 19.7 % |
| Qtrly Rev. Growth | 7.4 % |
| Gross Profit (p.s.) | 63.88 |
| Sales Per Share | 72.55 |
| EBITDA (p.s.) | 36.5 |
| Qtrly Earnings Growth | 24.5 % |
| Operating Cash Flow | 1,560 (M) |
| Levered Free Cash Flow | 582 (M) |
| PE Ratio | 21.11 |
| PEG Ratio | 0 |
| Price to Book value | 3.61 |
| Price to Sales | 8.1 |
| Price to Cash Flow | 16.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|